Betamethasone + Fusidic acid

Generic Medicine Info
Indications and Dosage
Corticosteroid-responsive dermatoses with secondary infection
Adult: Available preparations
Each cream contains betamethasone valerate 0.1 % and fusidic acid 2%
Each cream contains betamethasone dipropionate 0.064% and fusidic acid 2%
Each oint contains betamethasone dipropionate 0.064% and sodium fusidate 2%

Apply onto affected area(s) bid. Max duration: 2 weeks.
Skin lesions of viral, fungal or bacterial origin (e.g. herpes or varicella), skin manifestations in relation to TB or syphilis, perioral dermatitis and rosacea, ulcerative condition.
Special Precautions
May increase risk of developing antibiotic resistance. Stasis dermatitis and other skin disease w/ impaired circulation. Not to be used for >7 days if there is no clinical improvement. Avoid prolonged continuous treatment esp in infants and childn. Pregnancy and lactation.
Adverse Reactions
Hypersensitivity, contact dermatitis, eczema (aggravated condition), skin burning sensation, pruritus, dry skin, application site pain or irritation. Rarely, erythema, urticaria (including rash erythematous and generalised rash), application site swelling or vesicles.
Patient Counseling Information
Avoid contact w/ eyes as it may cause glaucoma.
Symptoms: Cushing's syndrome and adrenocortical insufficiency. Management: Symptomatic treatment.
Mechanism of Action: Betamethasone is a topical fluorinated corticosteroid that has an anti-inflammatory and antipruritic effect. Fusidic acid is a potent topical antibacterial agent which is effective against Staphylococcus aureus, Streptococci, Corynebacteria, Neiserria and certain Clostridia and Bacteroides.
Absorption: Betamethasone: Absorption through the skin is increased under occlusive dressing or when there is broken skin at the site of application.
Distribution: Betamethasone: Bound to plasma proteins to varying extent. Fusidic acid: Widely distributed into tissues and body fluids (including bone, pus, synovial fluid); penetrate cerebral abscesses but does not enter cerebrospinal fluid in appreciable amounts. Enters foetal circulation and breast milk. Plasma protein binding: Approx ≥95% as fusidic acid or Na fusidate.
Metabolism: Betamethasone: Mainly metabolised in the liver and limited extent in the kidneys.
Excretion: Betamethasone: Via urine as inactive metabolites. Fusidic acid/Na fusidate: Mainly in the bile via faeces (approx 2%) as unchanged drug; urine (small amounts).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Betamethasone, CID=9782, (accessed on Jan. 21, 2020)

Chemical Structure Image
Fusidic acid

Source: National Center for Biotechnology Information. PubChem Database. Fusidic acid, CID=3000226, (accessed on Jan. 21, 2020)

Store at or below 30°C. Protect from light.
MIMS Class
Topical Anti-Infectives with Corticosteroids
Fobancort (Hoe Pharma/Taisho PharmaceuticaL). MIMS Singapore. Accessed 07/08/2015.

Leo Pharma Ltd. Fucicort Cream data sheet January 2016. Medsafe. Accessed 07/08/2015.

Disclaimer: This information is independently developed by MIMS based on Betamethasone + Fusidic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Defuzin-B
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in